AstraZeneca contacted Gilead over potential megamerger: Bloomberg News
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Bristol-Myers Squibb (BMY), UbiVac Announce Clinical Trial Collaboration on Combination Immunotherapy for Advanced Triple Negative Breast Cancer
June 9, 2020 11:25 AM EDTBristol Myers Squibb (NYSE: BMY) and UbiVac, Inc. today announce they will enter into a clinical trial collaboration to evaluate the safety, tolerability, and preliminary efficacy of UbiVacs investigational product, DPV-001, a first-in-class cancer vaccine that exploits autophagy, in combination with Bristol Myers Squibbs anti-OX40 (BMS-986178) combined with sequenced administration of the programmed death-1 (PD-1) immune checkpoint inhibitor,... More
AstraZeneca (AZN) CEO Soriot Said to Have Called Gilead (GILD) CEO on May 9, Proposed Exploring Merger to O'Day on Call - Bloomberg
June 8, 2020 5:04 PM EDTAstraZeneca (NYSE: AZN) CEO Soriot Said to Have Called Gilead (NASDAQ: GILD) CEO on May 9, Proposed Exploring Merger to O'Day on Call - Bloomberg
... MoreGilead Sciences (GILD) Worth $120+ in Rumored Takeover - Piper Sandler
June 8, 2020 9:49 AM EDTPiper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $90.00 price target on Gilead Sciences (NASDAQ: GILD) following rumor of a potential deal with AstraZeneca (NYSE: AZN). Van Buren sees Gilead worth $120+ per share in a deal.
The analyst commented, "The... More
Eli Lilly & Co. (LLY), Junshi Biosciences Report First Healthy Volunteer Dosing in Phase I Clinical Study of SARS-CoV-2 Neutralizing Antibody JS016 in China
June 8, 2020 5:55 AM EDTJunshi Biosciences today announced that the first healthy volunteer has been dosed in the Phase I clinical study of JS016 at Huashan Hospital Affiliated to Fudan University in China. JS016 is the first SARS-CoV-2 neutralizing antibody to enter clinical trials in China. Junshi and Eli Lilly and Company (NYSE: LLY) are collaborating to co-develop JS016 globally, with Junshi leading clinical development in China and Lilly leading clinical development in the rest of the world.
The trial is a randomized, double-blind and placebo-controlled study to evaluate the tolerability, safety and pharmacokinetic and... More
